Trial Profile

Phase I, Safety and Immunogenicity of Gardasil in Systemic Lupus Erythematosus

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
Indications Cervical cancer; Human papillomavirus infections
Focus Adverse reactions
Acronyms GARDASIL

Most Recent Events

16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
21 Apr 2017 Status changed from active, no longer recruiting to completed, according to the results published in the Vaccine.
09 Apr 2017 Results evaluating the safety and immunogenicity published in the Vaccine.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com